BPaL Regimen (Bedaquiline, Pretomanid, Linezolid)
Treatment for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
Typical Dosage: Bedaquiline: 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid: 200mg daily for 26 weeks; Linezolid: 300-600mg daily for 26 weeks
Effectiveness
90%
Safety Score
58%
Clinical Trials
15
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline: 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid: 200mg daily for 26 weeks; Linezolid: 300-600mg daily for 26 weeks
Time to Effect
1-2 months for significant clinical improvement
Treatment Duration
6 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2.5(Treat 2.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$3,500
Side Effect Mgmt:$3,000
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$51,667
Cost per Remission
$51,667
Comparison vs Longer-course individualized MDR-TB regimens
Cost Difference
$-15,000/year
Less expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
BPaL Regimen (Bedaquiline, Pretomanid, Linezolid) Outcomes
for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+90%
Common Side Effects
Peripheral neuropathy
+60%
Myelosuppression (anemia, thrombocytopenia)
+15%
QT prolongation
+8%
Optic neuropathy
+6%
Nausea/vomiting
+18%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov